Details for Patent: 8,945,063

Which drugs does patent 8,945,063 protect, and when does it expire?

Patent 8,945,063 protects OTREXUP and is included in one NDA.

This patent has twelve patent family members in seven countries.

Summary for Patent: 8,945,063

Title:	Hazardous agent injection system
Abstract:	Injection systems comprising a powered injector and one or more hazardous agents are disclosed.
Inventor(s):	Wotton; Paul K. (Newton, PA), Sadowski; Peter L. (Woodbury, MN), Hayes; John William (Chaska, MN)
Assignee:	Antares Pharma, Inc. (Ewing, NJ)
Application Number:	14/158,289
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,945,063
Patent Claim Types: see list of patent claims	Formulation; Dosage form; Use;

Drugs Protected by US Patent 8,945,063

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Otter Pharms	OTREXUP	methotrexate	SOLUTION;SUBCUTANEOUS	204824-005	Nov 7, 2014		DISCN	Yes	No			Y			SUBCUTANEOUS INJECTION OF METHOTREXATE
Otter Pharms	OTREXUP	methotrexate	SOLUTION;SUBCUTANEOUS	204824-001	Oct 11, 2013		RX	Yes	Yes			Y			SUBCUTANEOUS INJECTION OF METHOTREXATE
Otter Pharms	OTREXUP	methotrexate	SOLUTION;SUBCUTANEOUS	204824-006	Mar 24, 2016		RX	Yes	Yes			Y			SUBCUTANEOUS INJECTION OF METHOTREXATE
Otter Pharms	OTREXUP	methotrexate	SOLUTION;SUBCUTANEOUS	204824-002	Oct 11, 2013		RX	Yes	Yes			Y			SUBCUTANEOUS INJECTION OF METHOTREXATE
Otter Pharms	OTREXUP	methotrexate	SOLUTION;SUBCUTANEOUS	204824-007	Mar 24, 2016		RX	Yes	Yes			Y			SUBCUTANEOUS INJECTION OF METHOTREXATE

International Family Members for US Patent 8,945,063

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2010226442
Canada	2755779
China	102612381
European Patent Office	2408493
Japan	2012521224